Tech Company Financing Transactions

Intellia Therapeutics Funding Round

Intellia Therapeutics, based in Cambridge, scored $15 million in investment from Atlas Venture, Novartis BioVenture Fund and private investors.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

40 Erie St.
Cambridge, MA 02139
USA

Phone

857-285-6200

Website

www.intelliatx.com

Email Address

Not Recorded

Overview

Intellia (NASDAQ: NTLA) is a leading gene editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

John Leonard

        

Chief Financial Officer

Glenn Goddard

        

Vice President

Eliana Clark

        

VP - Bus. Development

Christine Foster

        

VP - General Counsel

Nishla Keiser

        

VP - General Counsel

Jose Rivera

        

Browse more venture capital transactions:

Prev: 11/19/2014: V-Key venture capital transaction
Next: 11/19/2014: Bipsync venture capital transaction

Share this article

Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary